Editorial
Emerging trends on drug use globally
Jack E. Fincham,
Jack E. Fincham
Pharmaceutical Care and Administration, Presbyterian College, School of Pharmacy, Clinton, SC, USA
Search for more papers by this authorJack E. Fincham,
Jack E. Fincham
Pharmaceutical Care and Administration, Presbyterian College, School of Pharmacy, Clinton, SC, USA
Search for more papers by this authorFirst published: 26 July 2016
No abstract is available for this article.
References
- 1Parker-Lue S, Santoro M, Koski G. The ethics and economics of pharmaceutical pricing. Ann Rev Pharmacol Toxicol 2015; 55: 191–206.
- 2Reich MR, Shibuya K. The future of Japan's health system—sustaining good health with equity at low cost. N Engl J Med 2015; 373: 1793–1797.
- 3Boseley S. UK NHS Cancer Patients Denied Drugs Due To Inflated Prices-Experts. https://www.theguardian.com/business/2015/sep/23/uk-cancer-patients-being-denied-drugs-due-to-inflated-prices-say-experts (accessed 13 June 2016).
- 4van Harten W et al. Actual cost of cancer drugs in 15 European countries. Lancet Oncol 2016; 17: 18–20.
- 5Dranitsarus G. Health technology assessment of cancer drugs in Canada, the United Kingdom and Australia: should the United States take notice. Appl Health Econ Health Policy 2015; 13: 291–302.
- 6Ruggeri K, Nolte E. Pharmaceutical Pricing, the Use of External Reference Pricing. Santa Monica, California: RAND Corporation, 2013.
- 7Rankin P, Baldwin P. Rising drug prices and PBM practices in the spotlight. Consult Pharm 2015; 31: 56.
10.4140/TCP.n.2016.56 Google Scholar
- 8Bach P. New math on drug cost-effectiveness. N Eng J Med 2015; 373: 1797–1799.
- 9Neumann P, Cohen J. Measuring the value of prescription drugs. N Engl J Med 2015; 373: 2295–2597.
- 10Aitken M. Global Medicines Use in 2020. Parsipony, NJ: IMS Institute for Healthcare Informatics, 2015.
- 11Gray A et al. Essential medicines are still essential. Lancet 2015; 386: 1601–1603.
- 12Shulman LN et al. Proposing essential medicines to treat cancer: methodologies, processes, and outcomes. J Clin Oncol 2016; 34: 69–75.
- 13Eniu A et al. Back to the ‘essence’ of medical tereatment in oncology: the 2015 WHO Model list of essential medicines. ESMO Open 2016; 1: e000030. doi:10.1136/esmoopen-2015-000030.
- 14Kumar B, Baldi A. The challenge of counterfeit drugs: a comprehensive review on prevalence, detection and prevention measures. Curr Drug Saf 2016; 11: 112–120.
- 15Kelesidis T, Falagas ME. Substandard/counterfeit antimicrobial drugs. CMR 2015; 28: 443–464.
- 16Hensey CC, Gwee A. Counterfeit drugs: an Australian perspective. MJA 2016; 204: 344–344.e1.
- 17Gaudiano MC et al. Health risks related to illegal and on-line sale of drugs and food supplements: results from a survey on marketed products in Italy from 2011 to 2013. Ann 1st Super Sanita 2016; 52: 128–132.
- 18Nayyar G et al. Responding to the pandemic of falsified medicine. Am J Trop Med Hyg 2015; 92(Suppl 6): 113–118.
